Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 16;13(14):3556. doi: 10.3390/cancers13143556

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Precision medicine-mediated patient profiling for mCRPC management. Besides routine diagnostics, multiple screenings should be included in the diagnostic process. Genomic analysis for mutation status such as BRCA1/2, PTEN, AR and others should be combined with gene expression analysis and subsequent analysis of interactions and networks. ⁶⁸Ga-PSMA-PET/CT is an indispensable component of this screening process and allows detection of tumor distribution and load. mCRPC: metastatic castration-resistant prostate cancer; BRCA1/2: breast cancer 1/2 gene; PTEN: phosphatase and tensin homolog on chromosome ten; AR: androgen receptor; 68Ga: 68Gallium; PSMA: prostate-specific membrane antigen; PET/CT: positron-emission tomography/computer tomography. This figure was generated using biorender, www.biorender.com, accessed on 8 July 2021.